From: Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Disease types
Molecular markers
PTEN loss
PIK3CA mutation/amplification
Gasric cancer
4
1
Colorectal cancer
3
-
Pancreastic cancer
Cholangiocarcinoma